An understanding of how we can impact on brain wiring and functioning is the key to treat neurological disorders and a core to mind-fullness training that aims to the rewiring of the brain. The emergence of the research that clarifies the neurological mechanisms of integrated modulators that regulate changes in genes, cells, the brain, and new treatments for depression leads towards research methods such as fMRI, Genetic study, LDAEP, HRV, and treatment responsiveness to determine the disorders caused by genetic deregulation and environmental stimuli. A pathophysiological disorder results from biochemical, metabolic, neurophysiologic and genetic dynamic processes set in motion that leads to deranged function in an organ. The molecular neurobiological mechanisms such as genetic biomarkers, neural circuitry, and neuroplasticity associated with neurological diseases have been discussed in this review. This study involves a discussion of genes such as MiR-218, ARC, TH, SLC6A4, PCLO, rapid-acting antidepressants such as N-methyl-D-aspartate, Ketamine with the promise of dramatically improving treatment options for depressed patients. The objective of this study is to understand how these genes and compounds affect the brain and to find ways that can be used in treating behavioral disorders. Here, we review the current understanding of up and down regulation effects of the genes mentioned above, how rapid-acting antidepressants to function, including their merits and demerits with their application in biotechnology-based strategies for treatment and the research techniques being used to address these approaches.
